{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T10:08:29Z","timestamp":1785319709271,"version":"3.55.0"},"reference-count":30,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The OptiTROP-Breast01 trial demonstrated the efficacy of sacituzumab tirumotecan for patients with metastatic triple-negative breast cancer (TNBC). The current analysis evaluated the cost-effectiveness of sacituzumab tirumotecan compared with chemotherapy for patients with metastatic TNBC from the Chinese health-care system perspective.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A partitioned survival model (PSM) was developed to simulate 3-week patients in 10-year time horizon to access the disease course and cost-effectiveness of sacituzumab tirumotecan compared with chemotherapy for metastatic TNBC patients, cost and utility values were gathered from the dataset and published studies, annual discount rate of 5% was used. Total cost, life-years (LYs), quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratio (ICER) were the model outputs. Sensitivity analyses and subgroup analyses were conducted to estimate the robustness of the model outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In base-case analysis, compared with chemotherapy, sacituzumab tirumotecan could bring additional 0.41 LYs and 0.35 QALYs, with marginal costs of $55,927.31, resulting in the ICER of $162,799.04\/QALY, which high than the willingness-to-pay (WTP) threshold of $40,326 per additional QALY gained. One-way sensitivity analyses revealed that the utility value was the main driver of the model outputs. Probabilistic sensitivity analyses showed the cost-effective probability of sacituzumab tirumotecan was 0% at the WTP threshold of $40,326\/QALY. Subgroup analyses suggested that sacituzumab tirumotecan could not be considered cost-effective for all subgroup patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Sacituzumab tirumotecan was unlikely to be the cost-effective option for patients with metastatic TNBC compared with chemotherapy from the Chinese health-care system perspective, reduced the price of sacituzumab tirumotecan could increase its cost-effective.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0343330","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T18:21:48Z","timestamp":1772821308000},"page":"e0343330","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cost-effectiveness of sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer in China"],"prefix":"10.1371","volume":"21","author":[{"given":"Shuo","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yize","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5170-6771","authenticated-orcid":true,"given":"Shan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,3,6]]},"reference":[{"issue":"3","key":"pone.0343330.ref001","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"H Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"10159","key":"pone.0343330.ref002","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/S0140-6736(18)32335-3","article-title":"Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"392","author":"GBD 2017 DALYs and HALE Collaborators","year":"2018","journal-title":"Lancet"},{"issue":"25","key":"pone.0343330.ref003","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.2217\/fon-2018-0131","article-title":"Antibody-drug conjugates in triple negative breast cancer","volume":"14","author":"N Tray","year":"2018","journal-title":"Future Oncol"},{"issue":"16","key":"pone.0343330.ref004","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"A Bardia","year":"2021","journal-title":"N Engl J Med"},{"key":"pone.0343330.ref005","doi-asserted-by":"crossref","first-page":"951589","DOI":"10.3389\/fonc.2022.951589","article-title":"Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132","volume":"12","author":"Y Cheng","year":"2022","journal-title":"Front Oncol"},{"key":"pone.0343330.ref006","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2025-085680","article-title":"Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial","volume":"389","author":"W Fang","year":"2025","journal-title":"BMJ"},{"issue":"6","key":"pone.0343330.ref007","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1038\/s41591-025-03630-w","article-title":"Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial","volume":"31","author":"Y Yin","year":"2025","journal-title":"Nat Med"},{"issue":"5","key":"pone.0343330.ref008","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1524-4733.2004.75003.x","article-title":"Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?","volume":"7","author":"H-G Eichler","year":"2004","journal-title":"Value Health"},{"issue":"5","key":"pone.0343330.ref009","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s40273-017-0606-1","article-title":"Cost-Effectiveness Thresholds: the Past, the Present and the Future","volume":"36","author":"P Thokala","year":"2018","journal-title":"Pharmacoeconomics"},{"key":"pone.0343330.ref010","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.vhri.2023.02.006","article-title":"Does a Standard Cost-Effectiveness Threshold Exist? The Case of Greece","volume":"36","author":"C Tzanetakos","year":"2023","journal-title":"Value Health Reg Issues"},{"key":"pone.0343330.ref011","volume-title":"China guidelines for pharmacoeconomic evaluations","author":"G Liu","year":"2020"},{"key":"pone.0343330.ref012","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"P Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"key":"pone.0343330.ref013","doi-asserted-by":"crossref","DOI":"10.18637\/jss.v070.i08","article-title":"flexsurv: A Platform for Parametric Survival Modeling in R","volume":"70","author":"CH Jackson","year":"2016","journal-title":"J Stat Softw"},{"issue":"10","key":"pone.0343330.ref014","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s40261-019-00820-6","article-title":"Cost-effectiveness analysis of pembrolizumab plus axitinib versus sunitinib in first-line advanced renal cell carcinoma in China","volume":"39","author":"J Chen","year":"2019","journal-title":"Clin Drug Investig"},{"key":"pone.0343330.ref015","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.lungcan.2018.11.029","article-title":"Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China","volume":"127","author":"X Gu","year":"2019","journal-title":"Lung Cancer"},{"issue":"5","key":"pone.0343330.ref016","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1080\/14737167.2016.1222907","article-title":"Health state utility values in locally advanced and metastatic breast cancer by treatment line: a systematic review","volume":"16","author":"N Paracha","year":"2016","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"5","key":"pone.0343330.ref017","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1177\/0272989X12458348","article-title":"Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM modeling good research practices task force working group-6","volume":"32","author":"AH Briggs","year":"2012","journal-title":"Med Decis Making"},{"key":"pone.0343330.ref018","article-title":"Economic evaluation of sacituzumab govitecan for the treatment of metastatic triple-negative breast cancer in China and the US","volume":"11","author":"J Chen","year":"2021","journal-title":"Front Oncol"},{"key":"pone.0343330.ref019","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.breast.2023.02.003","article-title":"Cost-effectiveness of sacituzumab govitecan versus chemotherapy in advanced or metastatic triple-negative breast cancer","volume":"68","author":"Y Lang","year":"2023","journal-title":"Breast"},{"issue":"7","key":"pone.0343330.ref020","doi-asserted-by":"crossref","DOI":"10.1016\/j.clbc.2024.04.010","article-title":"Cost-effectiveness of sacituzumab govitecan versus single-agent chemotherapy for patients with metastatic triple-negative breast cancer in China","volume":"24","author":"L Wang","year":"2024","journal-title":"Clin Breast Cancer"},{"issue":"1","key":"pone.0343330.ref021","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1186\/s12913-023-09728-6","article-title":"Cost-effectiveness of sacituzumab govitecan versus chemotherapy in patients with relapsed or refractory metastatic triple-negative breast cancer","volume":"23","author":"J Xie","year":"2023","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"pone.0343330.ref022","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12962-024-00539-y","article-title":"Cost-effectiveness of sacituzumab govitecan versus single-agent chemotherapy for metastatic triple-negative breast cancer: a trial-based analysis","volume":"22","author":"Y Wu","year":"2024","journal-title":"Cost Eff Resour Alloc"},{"issue":"9","key":"pone.0343330.ref023","doi-asserted-by":"crossref","first-page":"3761","DOI":"10.1007\/s12325-020-01418-7","article-title":"Economic evaluation of cisplatin plus gemcitabine versus paclitaxel plus gemcitabine for the treatment of first-line advanced metastatic triple-negative breast cancer in China: using markov model and partitioned survival model","volume":"37","author":"M Rui","year":"2020","journal-title":"Adv Ther"},{"issue":"1","key":"pone.0343330.ref024","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1186\/s12916-022-02516-9","article-title":"A cost-effectiveness analysis of capecitabine maintenance therapy versus routine follow-up for early-stage triple-negative breast cancer patients after standard treatment from a perspective of Chinese society","volume":"20","author":"J-B Li","year":"2022","journal-title":"BMC Med"},{"issue":"1","key":"pone.0343330.ref025","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s40425-018-0440-9","article-title":"Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma","volume":"6","author":"B Wu","year":"2018","journal-title":"J Immunother Cancer"},{"key":"pone.0343330.ref026","doi-asserted-by":"crossref","first-page":"11383","DOI":"10.2147\/CMAR.S272149","article-title":"Cetuximab plus chemotherapy versus chemotherapy alone in recurrent or metastatic head and neck squamous cell carcinoma: a cost-effectiveness analysis","volume":"12","author":"Y Lang","year":"2020","journal-title":"Cancer Manag Res"},{"issue":"12","key":"pone.0343330.ref027","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1007\/s40261-020-00973-9","article-title":"Pembrolizumab vs the EXTREME regimen in recurrent or metastatic head and neck squamous cell carcinoma: a cost-effectiveness analysis","volume":"40","author":"Y Lang","year":"2020","journal-title":"Clin Drug Investig"},{"issue":"1","key":"pone.0343330.ref028","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1200\/JCO.21.02473","article-title":"Cost-effectiveness of pharmacologic treatment options for women with endocrine-refractory or triple-negative metastatic breast cancer","volume":"41","author":"SB Wheeler","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10","key":"pone.0343330.ref029","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.6004\/jnccn.2020.7796","article-title":"Cost-effectiveness analysis of durvalumab plus chemotherapy in the first-line treatment of extensive-stage small cell lung cancer","volume":"19","author":"D Ding","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"pone.0343330.ref030","doi-asserted-by":"crossref","DOI":"10.1111\/ajco.12477","article-title":"Health state utilities in non-small cell lung cancer: An international study","volume":"13","author":"B Nafees","year":"2017","journal-title":"Asia Pac J Clin Oncol"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0343330","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T18:21:53Z","timestamp":1772821313000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0343330"}},"subtitle":[],"editor":[{"given":"Jincheng","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,3,6]]},"references-count":30,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,6]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0343330","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,6]]}}}